Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Public ClinicalTrials.gov record NCT00960440. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors
Study identification
- NCT ID
- NCT00960440
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 399 participants
Conditions and interventions
Conditions
Interventions
- CP-690,550 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- Dec 18, 2018
2009 – 2011
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095 | — |
| Pfizer Investigational Site | San Diego | California | 92108 | — |
| Pfizer Investigational Site | Farmington | Connecticut | 06030-5353 | — |
| Pfizer Investigational Site | Trumbull | Connecticut | 06611 | — |
| Pfizer Investigational Site | Aventura | Florida | 33180 | — |
| Pfizer Investigational Site | Tampa | Florida | 33614 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30342 | — |
| Pfizer Investigational Site | Boise | Idaho | 83702 | — |
| Pfizer Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62704 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46227 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70115 | — |
| Pfizer Investigational Site | Portland | Maine | 04102 | — |
| Pfizer Investigational Site | Cumberland | Maryland | 21502 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01610 | — |
| Pfizer Investigational Site | Flowood | Mississippi | 39232 | — |
| Pfizer Investigational Site | Tupelo | Mississippi | 38801 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Pfizer Investigational Site | Voorhees Township | New Jersey | 08043 | — |
| Pfizer Investigational Site | Rocky Mount | North Carolina | 27804 | — |
| Pfizer Investigational Site | Bethlehem | Pennsylvania | 18015-1153 | — |
| Pfizer Investigational Site | Willow Grove | Pennsylvania | 19090 | — |
| Pfizer Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| Pfizer Investigational Site | Hixson | Tennessee | 37343 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37909 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Fort Worth | Texas | 76107 | — |
| Pfizer Investigational Site | Houston | Texas | 77034 | — |
| Pfizer Investigational Site | Lubbock | Texas | 79424 | — |
| Pfizer Investigational Site | Vancouver | Washington | 98664 | — |
| Pfizer Investigational Site | Vancouver | Washington | 98684 | — |
| Pfizer Investigational Site | Vancouver | Washington | 98686 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00960440, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2018 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00960440 live on ClinicalTrials.gov.